A Polymeric mRNA Vaccine Featuring Enhanced Site‐Specific mRNA Delivery and Inherent STING‐Stimulating Performance for Tumor Immunotherapy
Advanced Materials · 2025-04 · 37 (17)
DOI: 10.1002/adma.202410998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 17.03.2025. Verfasst von Xiaoya Guo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, RNA, Messenger, Membrane Proteins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, The talent cultivation project Funds for the Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province.
Abstract (Originalsprache)
The development of mRNA delivery carriers with innate immune stimulation functions has emerged as a focal point in the field of mRNA vaccines. Nonetheless, the expression of mRNA in specific sites and innate immune stimulation at specific sites are prerequisites for ensuring the safety of mRNA vaccines. Based on the synthetic PEIRs carriers library, this study identifies an innovative mRNA delivery carrier named POctS with the following characteristics: 1) simultaneously possessing high mRNA delivery efficiency and stimulator of interferon genes (STING) stimulation function. 2) Leveraging the distinctive site‐specific delivery capabilities of POctS, the expression of mRNA at specific sites and the activation of innate immune responses at designated sites are achieved, minimizing formulation toxicity and maximizing the vaccine performance. 3) Tailoring two types of mRNA vaccines based on POctS according to the immune infiltration status of different types of tumors. Briefly, POctS‐loading ovalbumin (OVA) mRNA as a tumor antigen vaccine achieves the prevention and treatment of melanoma in mice. Further, POctS‐loading mixed lineage kinase domain‐like protein (MLKL) mRNA as an in situ tumor vaccine effectively treats orthotopic pancreatic cancer in mice. This delivery carrier offers a feasible mRNA vaccine‐based immunotherapy strategy for various types of tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, 230026, China.
- State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), Xiamen Uni…
ORCID-Profile: Huayu Tian
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- The talent cultivation project Funds for the Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province
Zitieren
APA
Guo, X., Yang, Z., Guo, Z., Lai, H., Meng, H., Meng, M., Li, T., Li, Z., Chen, J., Feng, Y., Pang, X., Tian, H., & Chen, X. (2025). A Polymeric mRNA Vaccine Featuring Enhanced Site‐Specific mRNA Delivery and Inherent STING‐Stimulating Performance for Tumor Immunotherapy. Advanced Materials, 37(17). https://doi.org/10.1002/adma.202410998
Vancouver
Guo X, Yang Z, Guo Z, Lai H, Meng H, Meng M, et al. A Polymeric mRNA Vaccine Featuring Enhanced Site‐Specific mRNA Delivery and Inherent STING‐Stimulating Performance for Tumor Immunotherapy. Advanced Materials. 2025;37(17). doi:10.1002/adma.202410998
BibTeX
@article{Guo2025,
author = {Guo, Xiaoya and Yang, Zhiyu and Guo, Zhaopei and Lai, Huiyan and Meng, Hanyu and Meng, Meng and Li, Tong and Li, Zhen and Chen, Jie and Feng, Yuanji and Pang, Xuan and Tian, Huayu and Chen, Xuesi},
title = {A Polymeric mRNA Vaccine Featuring Enhanced Site‐Specific mRNA Delivery and Inherent STING‐Stimulating Performance for Tumor Immunotherapy},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {17},
doi = {10.1002/adma.202410998}
}
EUVIMED